When divided into low and high circulating COMP levels based on its median distribution in BA patients with the cut-off value of 128.47 ng/mL, a significant reduction in survival rate was detected in BA patients with unfavorable outcome combined with high circulating COMP levels (84.0%), compared with those with low circulating COMP levels (0%) (Log-rank: χ2 = 11.2, P = 0.001) (Fig. 2B). Here, COMP is linked to breast angiosarcoma.